Annual accounts receivable:
$601.99M+$201.66M(+50.37%)Summary
- As of today (August 20, 2025), SRPT annual accounts receivable is $601.99 million, with the most recent change of +$201.66 million (+50.37%) on December 31, 2024.
- During the last 3 years, SRPT annual accounts receivable has risen by +$449.00 million (+293.48%).
- SRPT annual accounts receivable is now at all-time high.
Performance
SRPT Accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly accounts receivable:
$527.29M-$132.08M(-20.03%)Summary
- As of today (August 20, 2025), SRPT quarterly accounts receivable is $527.29 million, with the most recent change of -$132.08 million (-20.03%) on June 30, 2025.
- Over the past year, SRPT quarterly accounts receivable has increased by +$167.30 million (+46.47%).
- SRPT quarterly accounts receivable is now -20.03% below its all-time high of $659.37 million, reached on March 31, 2025.
Performance
SRPT Quarterly accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
SRPT Accounts receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +50.4% | +46.5% |
| 3 y3 years | +293.5% | +129.0% |
| 5 y5 years | +562.4% | +406.9% |
SRPT Accounts receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +293.5% | -20.0% | +145.7% |
| 5 y | 5-year | at high | +562.4% | -20.0% | +420.3% |
| alltime | all time | at high | >+9999.0% | -20.0% | >+9999.0% |
SRPT Accounts receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $527.29M(-20.0%) |
| Mar 2025 | - | $659.37M(+9.5%) |
| Dec 2024 | $601.99M(+50.4%) | $601.99M(+38.5%) |
| Sep 2024 | - | $434.52M(+20.7%) |
| Jun 2024 | - | $360.00M(-5.0%) |
| Mar 2024 | - | $378.81M(-5.4%) |
| Dec 2023 | $400.33M(+86.5%) | $400.33M(+25.6%) |
| Sep 2023 | - | $318.86M(+34.6%) |
| Jun 2023 | - | $236.81M(+5.8%) |
| Mar 2023 | - | $223.84M(+4.3%) |
| Dec 2022 | $214.63M(+40.3%) | $214.63M(-3.9%) |
| Sep 2022 | - | $223.45M(-3.0%) |
| Jun 2022 | - | $230.28M(+17.5%) |
| Mar 2022 | - | $195.92M(+28.1%) |
| Dec 2021 | $152.99M(+51.0%) | $152.99M(+2.1%) |
| Sep 2021 | - | $149.79M(+17.5%) |
| Jun 2021 | - | $127.52M(+7.9%) |
| Mar 2021 | - | $118.20M(+16.6%) |
| Dec 2020 | $101.34M(+11.5%) | $101.34M(-16.8%) |
| Sep 2020 | - | $121.83M(+17.1%) |
| Jun 2020 | - | $104.03M(-2.7%) |
| Mar 2020 | - | $106.88M(+17.6%) |
| Dec 2019 | $90.88M(+85.3%) | $90.88M(+33.6%) |
| Sep 2019 | - | $68.03M(+19.4%) |
| Jun 2019 | - | $56.98M(+12.8%) |
| Mar 2019 | - | $50.51M(+3.0%) |
| Dec 2018 | $49.04M(+66.4%) | $49.04M(+0.9%) |
| Sep 2018 | - | $48.60M(+13.1%) |
| Jun 2018 | - | $42.98M(+7.9%) |
| Mar 2018 | - | $39.85M(+35.2%) |
| Dec 2017 | $29.47M(+463.7%) | $29.47M(+19.1%) |
| Sep 2017 | - | $24.75M(+39.1%) |
| Jun 2017 | - | $17.79M(+44.9%) |
| Mar 2017 | - | $12.28M(+134.9%) |
| Dec 2016 | $5.23M(+31.5%) | $5.23M(+31.2%) |
| Sep 2016 | - | $3.99M(+0.1%) |
| Jun 2016 | - | $3.98M(-0.2%) |
| Mar 2016 | - | $3.99M(+0.3%) |
| Dec 2015 | $3.98M | $3.98M(+45.5%) |
| Sep 2015 | - | $2.73M(+13.1%) |
| Jun 2015 | - | $2.42M(0.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2015 | - | $2.42M(0.0%) |
| Dec 2014 | $2.42M(-31.6%) | $2.42M(+180.3%) |
| Sep 2014 | - | $862.00K(-35.0%) |
| Jun 2014 | - | $1.33M(-83.1%) |
| Mar 2014 | - | $7.85M(+122.4%) |
| Dec 2013 | $3.53M(-25.1%) | $3.53M(-47.5%) |
| Sep 2013 | - | $6.72M(+77.4%) |
| Jun 2013 | - | $3.79M(-33.0%) |
| Mar 2013 | - | $5.65M(+19.9%) |
| Dec 2012 | $4.71M(+29.7%) | $4.71M(+90.5%) |
| Sep 2012 | - | $2.47M(-65.5%) |
| Jun 2012 | - | $7.18M(+39.8%) |
| Mar 2012 | - | $5.13M(+41.3%) |
| Dec 2011 | $3.63M(+74.2%) | $3.63M(-14.9%) |
| Sep 2011 | - | $4.27M(-60.8%) |
| Jun 2011 | - | $10.89M(-19.8%) |
| Mar 2011 | - | $13.58M(+159.0%) |
| Sep 2010 | - | $5.24M(+143.4%) |
| Jun 2010 | - | $2.15M(+30.6%) |
| Mar 2010 | - | $1.65M(-21.0%) |
| Dec 2009 | $2.08M(-58.1%) | $2.08M(-63.2%) |
| Sep 2009 | - | $5.67M(+68.8%) |
| Jun 2009 | - | $3.36M(+7.5%) |
| Mar 2009 | - | $3.13M(-37.1%) |
| Dec 2008 | $4.97M(+73.2%) | $4.97M(+21.9%) |
| Sep 2008 | - | $4.08M(+52.9%) |
| Jun 2008 | - | $2.67M(-34.2%) |
| Mar 2008 | - | $4.05M(+41.2%) |
| Dec 2007 | $2.87M(+5472.4%) | $2.87M(+63.9%) |
| Sep 2007 | - | $1.75M(+56.4%) |
| Jun 2007 | - | $1.12M(+102.9%) |
| Mar 2007 | - | $551.80K(+971.5%) |
| Dec 2006 | $51.50K(-95.8%) | $51.50K(-16.0%) |
| Sep 2006 | - | $61.30K(+38.1%) |
| Jun 2006 | - | $44.40K(-94.7%) |
| Mar 2006 | - | $840.20K(-32.0%) |
| Dec 2005 | $1.24M(>+9900.0%) | $1.24M |
| Dec 2000 | $0.00(0.0%) | - |
| Dec 1999 | $0.00(0.0%) | - |
| Dec 1998 | $0.00(0.0%) | - |
| Dec 1997 | $0.00 | - |
FAQ
- What is Sarepta Therapeutics, Inc. annual accounts receivable?
- What is the all time high annual accounts receivable for Sarepta Therapeutics, Inc.?
- What is Sarepta Therapeutics, Inc. annual accounts receivable year-on-year change?
- What is Sarepta Therapeutics, Inc. quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Sarepta Therapeutics, Inc.?
- What is Sarepta Therapeutics, Inc. quarterly accounts receivable year-on-year change?
What is Sarepta Therapeutics, Inc. annual accounts receivable?
The current annual accounts receivable of SRPT is $601.99M
What is the all time high annual accounts receivable for Sarepta Therapeutics, Inc.?
Sarepta Therapeutics, Inc. all-time high annual accounts receivable is $601.99M
What is Sarepta Therapeutics, Inc. annual accounts receivable year-on-year change?
Over the past year, SRPT annual accounts receivable has changed by +$201.66M (+50.37%)
What is Sarepta Therapeutics, Inc. quarterly accounts receivable?
The current quarterly accounts receivable of SRPT is $527.29M
What is the all time high quarterly accounts receivable for Sarepta Therapeutics, Inc.?
Sarepta Therapeutics, Inc. all-time high quarterly accounts receivable is $659.37M
What is Sarepta Therapeutics, Inc. quarterly accounts receivable year-on-year change?
Over the past year, SRPT quarterly accounts receivable has changed by +$167.30M (+46.47%)